Observes durvalumab after chemoradiation in limited stage small-cell lung cancer
Studies durvalumab as follow-up treatment in adults with limited small-cell lung cancer.
Plain-language title generated from the registry record
Registry title: Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China
Key facts
- Where
- Beijing, Cangzhou, Dongguan, Fuzhou, Guangzhou, Huzhou, Jinan, Nanjing, Nanning, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjing, Wuhan, Wuxi, Yangzhou, and Zhengzhou, ChinaSee the 19 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with limited stage small-cell lung cancer whose disease has not grown after chemotherapy plus radiation and who were given durvalumab afterwards.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Limited stage small-cell lung cancer (stage I-III, no spread to distant organs), confirmed by tissue or cell tests, that can be safely treated with full radiation doses. ECOG performance status 0-2.
- Earlier treatment
- Must have had platinum-based chemotherapy with radiation (at the same time or one after the other) with no disease progression, then durvalumab as the next treatment. Durvalumab must have started within 3 months after radiation ended. Must not have had durvalumab or other anti-PD-1/anti-PD-L1 drugs during chemoradiation, or any such immune therapy before.
Main reasons for not taking part
- Chemoradiation only, without durvalumab afterwards
- Durvalumab or another anti-PD-1/anti-PD-L1 drug given together with chemoradiation
- Taking part now, before or later in another interventional cancer trial for limited stage small-cell lung cancer
- Earlier immune therapy such as anti-PD-1, anti-PD-L1 or anti-PD-L2 antibodies (anticancer vaccines are not counted)
- Unlikely to follow the trial procedures, in the investigator's judgment
Read by machine on 12 November 2026.
Where in China
- BeijingHospital not named in the registryTaking people
- CangzhouHospital not named in the registryTaking people
- DongguanHospital not named in the registryTaking people
- FuzhouHospital not named in the registryTaking people
- GuangzhouHospital not named in the registryTaking people
- HuzhouHospital not named in the registryTaking people
- JinanHospital not named in the registryTaking people
- NanjingHospital not named in the registryTaking people
- NanningHospital not named in the registryTaking people
- NingboHospital not named in the registryTaking people
- ShanghaiHospital not named in the registryTaking people
- ShenyangHospital not named in the registryTaking people
- ShijiazhuangHospital not named in the registryTaking people
- TaiyuanHospital not named in the registryTaking people
- TianjingHospital not named in the registryTaking people
- WuhanHospital not named in the registryTaking people
- WuxiHospital not named in the registryTaking people
- YangzhouHospital not named in the registryTaking people
- ZhengzhouHospital not named in the registryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07161388
- Record updated
- 11 September 2026
- Original description
This prospective, multicentre, observational study aims to assess the effectiveness and safety of durvalumab as consolidation treatment for patients with LS-SCLC who have not progressed following CRT in real-world setting.Read full original descriptionShow less
Durvalumab Consolidation After Chemoradiation Therapy (CRT) for Patients With Limited Stage Small-Cell Lung Cancer in China: A Multicentre, Observational Study (DREAM)
This prospective, multicentre, observational study aims to assess the effectiveness and safety of durvalumab as consolidation treatment for patients with LS-SCLC who have not progressed following CRT in real-world setting.
Inclusion: Able to provide informed consent; Age ≥18 years; Histologically or cytologically documented LS-SCLC (Stage I-III SCLC [T any, N any, M0] according to the American Joint Committee on Cancer Staging Manual [AJCC Cancer Staging Manual, 8th Edition], that can be safely treated with definitive radiation doses. Excludes T3-4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan); ECOG PS 0-2 (prior to the first dose of durvalumab after CRT); No disease progression following cCRT/sCRT (cCRT refers to chemotherapy and radiotherapy are administered with overlap; sCRT refers to chemotherapy and radiotherapy are delivered in a sequential manner with no overlap); Patients who received platinum-based cCRT/sCRT followed by durvalumab consolidation as first-line treatment at the discretion of physicians are eligible (the time interval from the end of cCRT/sCRT to the first dose of durvalumab consolidation should be within 3 months); Patients who started durvalumab consolidation ≤3 months before enrolment in the study will be allowed (irrespective of whether they continue to receive durvalumab at time of enrolment or already discontinued treatment).
Exclusion: Patients treated with CRT only without subsequent durvalumab consolidation; Patients received durvalumab or any other anti-PD-1/anti-PD-L1 antibodies along with CRT; Patients who previously were involved, or currently are, or plan to be involved in any other interventional anti-cancer clinical studies for LS-SCLC; Prior exposure to immune-mediated therapy including, but not limited to, other anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies, excluding therapeutic anticancer vaccines; Judgment by the investigator that the patient should not participate in the study because the patient is unlikely to comply with study procedures.